Dennis W. Schneck - Concepedia

Author

Dennis W. Schneck

Also Known As

D SCHNECK, D Schneck, D W Schneck, D. Schneck, D. W. SCHNECK, D. W. Schneck, D.W Schneck, D.W. Schneck, DENNIS W. SCHNECK, Dennis Schneck

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)Pennsylvania State University Penn State Milton S. Hershey Medical Center Clinical Research Associates

About

Dennis W. Schneck is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	1.5K
2	Natural Sciences	3	3	465
3	Health Sciences	2	2	38
4	Public Health	1	1	10
5	Applied Physiology	1	1	20

Dennis W. Schneck

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Eminy H.Y. Lee, S RYAN, Bruce K. Birmingham, Clinical Pharmacology & Therapeutics	2005	473
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca. Fergus McTaggart, Linda K. Buckett, Robert G. Davidson, The American Journal of Cardiology Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceOxysterolBiochemistry	2001	412
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Dennis W. Schneck Clinical Pharmacology & Therapeutics	2004	293
Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers Paul Martin, Pat Mitchell, Dennis W. Schneck British Journal of Clinical Pharmacology	2002	150
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease Dennis W. Schneck, Robert H. Knopp, Christie M. Ballantyne, The American Journal of Cardiology HypertensionCardiovascular DiseaseMedicineDose RangesHyperlipidemia	2003	139
Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state Linda E. Gustavson, Joachim Kaiser, Anthony Edmonds, Antimicrobial Agents and Chemotherapy Gastric FundusGastric PhSteady StateMedicineGastrointestinal Pharmacology	1995	129
The effect of fluconazole on the pharmacokinetics of rosuvastatin Kevin D. Cooper, Paul Martin, Aaron Dane, European Journal of Clinical Pharmacology Pharmaceutical SciencePharmacological StudyMedicinePharmacotherapyPharmacology	2002	112
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers Paul Martin, Aaron Dane, Dennis W. Schneck, Clinical Therapeutics Pharmacological StudyCardiovascular DiseaseMedicineHealthy Male VolunteersThree-way Crossover Trial	2003	104
Studies on the uptake and binding of propranolol by rat tissues. Dennis W. Schneck, J. Frederick Pritchard, A. Hayes Journal of Pharmacology and Experimental Therapeutics	1977	95
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects K. J. Cooper, Paul Martin, Aaron Dane, British Journal of Clinical Pharmacology	2003	89

Page 1